- Trial phase
- Phase 1
- Time to market
- BGB-58067 is in Phase 1 testing with no pivotal trial started. Assuming successful Phase 1b results lead to a Phase 2/3 program, potential approval is likely several years away (2029 or later under an accelerated path).
- Why 3/10
- No hard, dated binary catalyst is scheduled in the next ~12 months. The Phase 1a data was already presented at ESMO 2026 (October 23-27). The drug remains in Phase 1b dose expansion with no PDUFA date, pivotal readout, or AdComm on the calendar. BeOne is a large, diversified oncology company (market cap ~$43.5B) with approved products and multiple pipeline programs, so BGB-58067 is one of several priority assets and not a single-stock binary.
BGB-58067's ESMO 2026 data is already public and priced in. The next meaningful catalyst will be Phase 1b combination-cohort data or a decision to advance to a registrational trial, neither of which has a confirmed date. For a company as diversified as BeOne, this single early-stage asset is unlikely to drive large stock moves on its own. Watch for combination data in 1L NSCLC and PDAC, and for any partnership or out-licensing moves in the PRMT5 space that could validate the asset.
Price Chart
Executive Summary
BGB-58067 is an oral, brain-penetrant MTA-cooperative PRMT5 inhibitor in Phase 1 testing for MTAP-deficient advanced solid tumors, developed by BeOne Medicines (Nasdaq: ONC, formerly BeiGene). Initial Phase 1a data presented at ESMO 2026 showed a 25.3% confirmed objective response rate in MTAP-deficient NSCLC (38.5% in EGFR wild-type), a 30.8% intracranial response rate in patients with brain metastases, and a manageable safety profile. The drug received FDA Orphan Drug Designation for pancreatic ductal adenocarcinoma in August 2026. However, it is still early-stage clinical development at a large, diversified biotech, and the MTA-cooperative PRMT5 inhibitor space is competitive (AMG 193, MRTX1719, TNG908 among others). No pivotal trial or regulatory decision is imminent.
How It Works
BGB-58067 is an oral pill that blocks a protein called PRMT5, which cancer cells need to grow. It is designed to work selectively in tumors that lack a gene called MTAP (about 15% of all cancers), where a natural molecule called MTA builds up. The drug only binds strongly to PRMT5 when MTA is present, so it mostly hits cancer cells while sparing healthy ones. It also crosses into the brain, which matters because many solid tumors spread there.
Trial Status
BGB-58067 is being studied in a first-in-human, open-label Phase 1a/b trial (NCT06589596) across 101 sites in 11 countries, targeting 244 participants with MTAP-deficient advanced solid tumors. The Phase 1a dose-escalation portion has completed enrollment and initial data were presented at ESMO 2026. The Phase 1b dose-expansion and combination-cohort portion is actively recruiting. A separate early-phase trial (NCT07485049) is studying BGB-58067 in newly diagnosed glioblastoma with MTAP deletion.
The Two-Sided Case
Upcoming Catalysts
- Phase 1b dose-expansion data from combination cohorts (1L NSCLC, PDAC) at a future medical conference (no date announced)
- Phase 0/2 data in glioblastoma from NCT07485049 (no date announced)
- Potential advancement to pivotal/registrational trial design disclosure
Source Filing
The SecBot filing or press-release report that triggered this drug report:
BeOne Medicines Ltd. 8-K ONC ·Originating report